Mabwell Receives the NMPA’s IND Approval of 9MW2921 for the Treatment of Solid Tumor
Shots:
- The NMPA has approved an IND application of 9MW2921 for the treatment of solid tumors patients
- 9MW2921 showed a better tumor-killing activity in vivo PD studies. The on-target and off-target toxicities of 9MW2921 were effectively controlled in animal safety evaluation models incl. cynomolgus monkeys and rats demonstrating the drug's favorable safety profile and PK properties
- 9MW2921, a next-generation ADC that is being developed using Mabwell's novel antibody-drug conjugate platform IDDC for solid tumors. Additionally, multiple ADC products are expected to enter clinical development in 2023 and 2024
Ref: PR Newswire | Image: Mabwell
Related News:- Mabwell’s Mailishu (biosimilar, denosumab) Receives the NMPA’s Approval for the Treatment of Osteoporosis in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
